Table 1.
Patient Characteristics
| Local therapy patients | Systemic therapy patients | P value | |
|---|---|---|---|
| Characteristic | N=18 | N=166 | |
| Age-year | |||
| Median | 57 | 58 | 0.67 |
| Range | 44–69 | 26–86 | |
| Sex-(%) | |||
| Male | 8 (44) | 56 (34) | 0.44 |
| Female | 10 (56) | 110 (66) | |
| Ethnicity-(%) | |||
| White | 13 (72) | 116 (70) | *0.99 |
| Asian | 4 (22) | 34 (20) | |
| Black | 1 (6) | 14 (8) | |
| Other | 0 | 2 (1) | |
| Smoking history- (%) | |||
| Never-smoker | 11 (61) | 116 (70) | 0.43 |
| Former smoker | 7 (39) | 50 (30) | |
| Median pack year | 20 | 16 | |
| Range | 1–56 | 1–60 | |
| Stage at initial diagnosis- (%) | |||
| I–II | 2 (11) | 22 (13) | 0.55 |
| IIIA–IIIB | 3 (17) | 15 (9) | |
| IVA–IVB | 13 (72) | 129 (78) | |
| Site of metastatic disease | |||
| Lung | 14 | 139 | 0.59 |
| Brain | 3 | 41 | |
| Bone | 4 | 65 | |
| Lymph node | 8 | 50 | |
| Visceral (liver, spleen, etc) | 2 | 32 | |
| EGFR mutation type- (%) | |||
| Exon 19 deletion | 14 (78) | 109 (66) | 0.63 |
| Exon 21 L858R | 4 (22) | 53 (32) | |
| Other | 0 | 4 (2) | |
| Best response to TKI | |||
| Complete response | 1 | 2 | 0.70 |
| Partial response | 13 | 130 | |
| Stable disease | 1 | 19 | |
| Adjuvant therapy | 3 | 13 | |
| Progression disease | 0 | 2 | |
| Initial EGFR TKI TTP (months) | |||
| Median | 19 | 12 | 0.089 |
| Range | 5– 33 | 2 – 73 | |
| Resistance mechanism-no (%) | |||
| T790M | 11 (61%) | 84 (51%) | **0.63 |
| MET amplification | 1 | 5 | |
| Small cell histology | 1 | 3 | |
| Unknown | 6 | 75 |
*
P value for white vs all others is 0.99
**
P value for T790M group vs. all others is 0.63